Drug resistance of human immunodeficiency virus and overcoming it by natural products

In Vivo

Volumn 23, Issue 1, 2009, Pages 1-6

  Hupfeld, Julia ^a   Efferth, Thomas ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Antiviral agents; Chemotherapy; Drug resistance; Human immunodeficiency virus; Natural products; Pharmacognosy; Review

Indexed keywords

3',4' DI O CAMPHANOYL KHELLACTONE; ANDROGRAPHOLIDE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIVIRUS AGENT; BETULIC ACID; BEVIRIMAT; CALANOLIDE A; EPIGALLOCATECHIN GALLATE; GERANIIN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; GLYCYRRHIZIC ACID; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; INTEGRASE INHIBITOR; NATURAL PRODUCT; PLACEBO; PLANT MEDICINAL PRODUCT; POLYCITONE A; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; BIOLOGICAL PRODUCT;

ANAPHYLAXIS; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; REVIEW; SIDE EFFECT; TASTE; VIRUS LOAD; VIRUS REPLICATION; ACQUIRED IMMUNE DEFICIENCY SYNDROME; CHEMISTRY; DRUG EFFECT; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; MEDICINAL PLANT; MUTATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; BIOLOGICAL PRODUCTS; DRUG RESISTANCE, VIRAL; HIV-1; HUMANS; MUTATION; PLANTS, MEDICINAL;

EID: 63049094312     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. AIDS Epidemic Update: December 2007. Joint United Nations Program on HIV and AIDS. UNAIDS, Geneva, Switzerland, 2007.
2. Johnson SC and Gerber JG: Advances in HIV/AIDS therapy. Adv Intern Med 45: 1-40, 2000.
3. Freed EO: HIV-1 replication. Somat Cell Mol Genet 26: 13-33, 2001.
4. Bout S, Geleziunas R and Wainberg MA: The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HLV-1 infection. Microbiol Rev 59: 63-93, 1995.
5. Doms RW and Peiper SC: Unwelcomed guests with master keys: how HIV uses chemokine receptors for cellular entry. Virology 235: 179-190, 1997.
6. Brown P: Integration. In: Retroviruses, JM Coffin and Varmus, HE (eds.). Cold Spring Harbor, Cold Spring Harbor Laboratory Press, pp. 161-203, 1997.
7. Garnier L, Wills JW, Verderame ME and Sudol M: WW domains and retrovirus budding. Nature 381: 744-745, 1996.
8. DHHS: Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents December 1, 2007. Department of Health and Human Services, AIDSinfo web site [online], http://AIDSinfo.nih.gov, 2007.
9. Hardy H and Skolnik PR: Enfuvirtide, a new fusion inhibitor for therapy of human immunodeficiency virus infection. Pharmacotherapy 24: 198-211, 2004.
10. Doff P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, Mori J, Rickett G, Smith Burchnell C, Napier C, Webster R, Armour D, Price D, Stammen B, Wood A and Perros M: Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 49: 4721-4732, 2005.
11. FDA: FDA Approves New HIV Drug - Raltegravir tablets used in combination with other antiretroviral agents. U.S. Food and Drug Administration.
12. Mansky LM and Temin HM: Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 69: 5087-5094, 1995.
13. MacNeil A, Sarr AD, Sankale JL, Meloni ST, Mboup S and Kanki P: Direct evidence of lower viral replication rates in vivo in human immunodeficiency virus type 2 (HIV-2) infection than in H1V-1 infection. J Virol 81: 5325-5330, 2007.
14. Flexner C: HIV drug development: the next 25 years. Nat Rev Drug Discov 6: 959-966, 2007.
15. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD: Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med 15: 119-125, 2007.
16. Calvez V, Costagliola D, Descamps D, Yvon A, Collin G, Cecile A, Delaugerre C, Damond F, Marcelin AG, Matheron S, Simon A, Valantin MA, Katlama C and Brun-Vezinet F: Impact of stavudine phenotype and thyrnidine analogues mutations on viral response to stavudine plus lamivudine in ALTIS 2 ANRS trial. Antivir Ther 7: 211-218, 2002.
17. Kuritzkes DR, Bassett RL, Hazelwood JD, Barrett H, Rhodes RA, Young RK and Johnson VA: Rate of thymidine analogue resistance mutation accumulation with zidovudine- or stavudine-based regimens. J Acquir Immune Defic Syndr 36: 600-603, 2004.
18. Asres K, Seyoum A, Veeresham C, Bucar F and Gibbons S: Naturally derived anti-HIV agents. Phytother Res 19: 557-581, 2005.
19. Cos P, Maes L, Vanden Berghe D, Hermans N, Pieters L and Vlietinck A: Plant substances as anti-HIV agents selected according to their putative mechanism of action. J Nat Prod 67: 284-293, 2004.
20. De Clercq E: Current lead natural products for the chemotherapy of human immunodeficiency virus (HIV) infection. Med Res Rev 20: 323-349, 2000.
21. Yu D, Morris-Natschke SL and Lee KH: New developments in natural products-based anti-AIDS research. Med Res Rev 27: 108-132, 2007.
22. Fujioka T, Kashiwada Y, Kilkuskie RE, Cosentino LM, Ballas LM, Jiang JB, Janzen WP, Chen IS and Lee KB: Anti-AIDS agents, 11. Betulinic acid and platanic acid as anti-HIV principles from Syzigium claviflorum, and the anti-HIV activity of structurally related triterpenoids. J Nat Prod 57: 243-247, 1994.
23. Panacos: A New Generation of Anti-Infective Drugs: Bevirimat (PA-457). Panacos Pharmaceuticals Inc., [online], http://www.panacos.com/ product_2.htm, 2008.
24. Li F, Goila-Gaur R, Salzwedel K, Kilgore NR, Reddick M, Matallana C, Castillo A, Zoumplis D, Martin DE, Orenstein JM, Allaway GP, Freed EO and Wild CT: PA-457: a potent HLV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc Natl Acad Sci USA 100: 13555-13560, 2003.
25. Kashman Y, Gustafson KR, Fuller RW, Cardellina JH, 2nd, McMahon JB. Currens MJ, Buckheit RW Jr, Hughes SH, Cragg GM and Boyd MR: The calanolides, a novel HIV inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum lanigerum. J Med Chem 35: 2735-2743, 1992.
26. Currens MJ, Gulakowski RJ, Mariner JM, Moran RA, Buckheit RW Jr, Gustafson KR, McMahon JB and Boyd MR: Antiviral activity and mechanism of action of calanolide A against the human immunodeficiency virus type-1. J Pharmacol Exp Ther 279: 645-651, 1996.
27. Currens MJ, Mariner JM, McMahon JB and Boyd MR: Kinetic analysis of inhibition of human immunodeficiency virus type-1 reverse transcriptase by calanolide A. J Pharmacol Exp Ther 279: 652-661, 1996.
28. Creagh T, Ruckle JL, Tolbert DT, Giltner J, Eiznhamer DA, Dutta B, Elavin MT and Xu ZQ: Safety and pharmacokinetics of single doses of (+) calanolide A, a novel, naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy, human immunodeficiency virus-negative human subjects. Antimicrob Agents Chemother 45: 1379-1386, 2001.
29. Sherer R DB, Anderson R, Laudette-Aboulhab J, Kamarulzaman A, D'Amico R, Paton N and Abdullah MS: A phase IB study of (+)-calanolide A in HIV-1-infected, antiretroviral therapy-naive patients. 7th Conf Retrovir Opportunistic Infect, abstract no. 508. San Francisco, CA, 2000.
30. Buckheit RW Jr, White EL, Eliakas-Boltz V, Russell J, Stup TL, Kinjerski TL, Osterling MC, Weigand A and Bader JP: Unique anti-human immunodeficiency virus activities of the nonnucleoside reverse transcriptase inhibitors calanolide A, costatolide, and dihydrocostatolide. Antimicrob Agents Chemother 43: 1827-1834, 1999.
31. Yamaguchi K, Honda M, Ikigai H, Hara Y and Shimamura T: Inhibitory effects of (-) epigallocatechin gallate on the life cycle of human immunodeficiency virus type 1 (HIV-1). Antiviral Res 53: 19-34, 2002.
32. Nakane H and Ono K: Differential inhibitory effects of some catechin derivatives on the activities of human immunodeficiency virus reverse transcriptase and cellular deoxyribonucleic and ribonucleic acid polymerases. Biochemistry 29: 2841-2845, 1990.
33. Williamson MP, McCormick TG, Nance CL and Shearer WT: Epigallocatechin gallate, the main polyphenol in green tea, binds to the T-cell receptor, CD4: Potential for HIV-1 therapy. J Allergy Clin Immunol 118: 1369-1374, 2006.
34. Yao WH, Zhao W, Wu YW, Zhao H, Wei HX, Cheng C, Zhu P and Chi Y: Effect of compound glycyrrhizin on peripheral T-lymphocyte subset in AIDS patients. Zhonghua Nan Ke Xue 12: 598-601, 2006 (in Chinese).
35. Ito M, Sato A, Hirabayashi K, Tanabe F, Shigeta S, Baba M, De Clercq E, Nakashima H and Yamamoto N: Mechanism of inhibitory effect of glycyrrhizin on replication of human immunodeficiency virus (HIV). Antiviral Res 10: 289-298, 1988.
36. Il'ina TV, Fediuk NV, Bachinskii AG, Tumanova O, Kuvshinov VN, Il'ichev AA and Pokrovskii AG: Determination of glycyrrhizic acid binding sites by a phage display method. Mol Biol (Mosk) 37: 861-867, 2003 (in Russian).
37. Calabrese C, Berman SH, Babish JG, Ma X, Shinto L, Dorr M, Wells K, Wenner CA and Standish LJ: A phase I trial of andrographolide in HIV-positive patients and normal volunteers. Phytother Res 14: 333-338, 2000.
38. Loya S, Rudi A, Kashman Y and Hizi A: Polycitone A, a novel and potent general inhibitor of retroviral reverse transcriptases and cellular DNA polymerases. Biochem J 344(Pt 1): 85-92, 1999.
39. Notka F, Meier GR and Wagner R: Inhibition of wild-type human immunodeficiency virus and reverse transcriptase inhibitor-resistant variants by Phyllanthus amarus. Antiviral Res 58: 175-186, 2003.
40. Yu D, Suzuki M, Xie L, Morris-Natschke SL and Lee KH: Recent progress in the development of coumarin derivatives as potent anti-HIV agents. Med Res Rev 23: 322-345, 2003.
41. Chen HF, Fan BT, Zhao CY, Xie L, Zhao CH, Zhou T, Lee KH and Allaway G: Computational studies and drug design for HIV-1 reverse transcriptase inhibitors of 3′,4′-di O-(S)-carnphanoyl-(+)-cis-khellactone (DCK) analogs. J Comput Aided Mol Des 19: 243-258, 2005.